Since neural stem cells (NSCs) have the ability to migrate toward a tumor mass, genetically engineered NSCs were used for the treatment of gliomas. We first evaluated the ''bystander effect'' between NSCs transduced with the herpes simplex virus-thymidine kinase (HSVtk) gene (NSCtk) and C6 rat glioma cells under both in vitro and in vivo conditions. A potent bystander effect was observed in co-culture experiments of NSCtk and C6 cells. In the intracranial co-implantation experiments in athymic nude mice and Sprague-Dawley rats, the animals co-implanted with NSCtk and C6 cells and treated with ganciclovir (GCV) showed no intracranial tumors and survived more than 100 days, while those treated with physiological saline (PS) died of tumor progression. We next injected NSCtk cells into the pre-existing C6 tumor in rats and treated them with GCV or PS. The tumor volume was serially measured by magnetic resonance imaging. The tumor disappeared in six out of nine rats in the NSCtk/GCV group, while all the rats treated with PS died of tumor progression by day 21. The results indicate the feasibility of a novel gene therapy strategy for gliomas through a bystander effect generated by intratumoral injection of NSCtk cells and systemic GCV administration.
R ecently, the understanding of gliomas has expanded in pace with advances in the field of molecular biology and genetics. Unfortunately, despite the continuous refinement of the techniques of diagnosis, surgical intervention, radiotherapy and/or chemotherapy, the prognosis for patients with malignant gliomas still remains poor, and only a minority of patients with certain subsets of brain tumors has experienced a prolonged survival. 1 A variety of some novel strategies have been pursued experimentally and clinically. One of these is ''gene therapy'' that can be defined as transfer of genetic materials into patient's cells for therapeutic purposes. The unique biologic features of adult malignant gliomas, such as high mitotic activity on an essentially postmitotic background and virtually no tumor spread outside the central nervous system, offer major advantages in the design of tumor-selective gene therapy strategies. To date, a diverse and creative assortment of treatment strategies utilizing gene therapy has been devised. Among them, the most feasible and wellestablished approach is the ''suicide gene therapy'', which is also called the enzyme/prodrug system because the suicide gene encodes an enzyme that modifies a nontoxic prodrug into a toxic molecule in the cells. The most widely used suicide gene therapy is the HSVtk/ganciclovir (GCV) system, which has already been tested in clinical trials. 2 As retroviral vectors, used in the first clinical trials, only transfer gene into dividing cells, this strategy is theoretically not harmful to the host brain.
A critical element in using the HSVtk/GCV system is the so-called ''bystander effect'', where brain tumor cells that were not transduced with the HSVtk suicide gene were eliminated along with HSVtk gene-transduced cells. 3 Although the mechanism is still not clear, it is considered that phosphorylated GCV is capable of passing through cellular gap junctions to confer cytotoxic effects on nontransduced neighboring cells. In our previous study using a rat brain tumor model, we tried to treat an established HSVtk-nontransduced brain tumor through the bystander effect by injecting HSVtk gene-transduced tumor cells (TK tumor cells) in the vicinity of the tumor, followed by GCV administration. 4 In the next experiment, we used allogeneic tumor cells, instead of syngeneic tumor cells, as TK tumor cells. 5 A potent bystander effect was also shown between the pre-existing tumor cells and injected TK tumor cells even when the TK tumor cells were allogeneic. The latter experimental setting was designed to translate this strategy to clinical trials. After taking out the bulk of the tumor with craniotomy surgery, sufficient amount of pre-established allogeneic TK tumor cells are applied on the tumor cavity where some residual tumor cells must still exist. GCV is then administered several days later when the injected TK tumor cells have migrated along with the tumor invasion route and mixed with the residual tumor cells even at a distant site. Finally, residual tumor cells are eradicated by the bystander effect. Though this strategy seems quite practical and promising, ethical problems still exist with the use of viable tumor cells even in recurrent gliomas that are inevitably fatal at the present time.
In the present study, we isolated neural stem cells (NSCs) from Sprague-Dawley rat embryos and expanded them using neural stem cell expansion kit/Neurosphere system (R&D Systems) and tested the use of NSCs, which recently have been shown to possess the ability to proliferate, migrate and then differentiate along the neuronal and glial lines, [6] [7] [8] as TK-expressing cells.
Materials and methods

Isolation of NSCs from 14-day Sprague-Dawley rat embryos
All the following experiments were performed according to the Rules of Animal Experimentation and the Guide for the Care and Use of Laboratory animals of the Hamamatsu University School of Medicine. Fetal cerebral hemisphere tissue was obtained from 14-day Sprague-Dawley rat embryos (Nippon SLC, Hamamatsu) and immediately dissected in chilled sterile PBS (pH 7.4) with .6% glucose. The tissue was mechanically dissociated with a fire-polished Pasteur pipette in NSC growth medium using the Neural stem cell expansion kit/Neurosphere system (R&D Systems, Inc., Minneapolis, MN). The culture medium was composed of DMEM-F12 medium (GIBCO, Invitrogen Corp., Grand Island, NY), N-2 plus media supplement (R&D Systems, Inc.), glucose (.155%), L-glutamate (3 mM), sodium bicarbonate (20 mM), and 100 U/ml of penicillin G and 100 mg/ml of streptomycin. After being passed through a 70 mm nylon strainer (FALCON, Becton Dickinson Labware, Franklin lakes, NJ), the cells were plated at a concentration of 4 Â 10 5 per ml in an ultra-low-attachment six-well cluster (COSTAR, Corning Inc., Corning, NY) and incubated at 371C under 5% CO 2 . The medium was supplemented with human EGF and human FGF basic (both at 20 ng/ml; R&D Systems Inc.) each day. Thereafter, bulk cultures were generated by transferring the free-floating spherical aggregates termed ''neurospheres'' as 1-1.5 Â 10 6 cells/ 5 ml into 25 cm 2 ultra-low-attachment tissue culture flasks (COSTAR, Corning Inc., Corning, NY).
Establishment of the NSCs with the HSVtk gene
The HSVtk retrovirus-producing cells (PA317; mouse fibroblast cell line with HSVtk gene) were kindly provided by Genetic Therapy Inc. (Gaithersburg, MD). The PA317 cells were cultured in NSC growth medium with 20 ng/ml of human FGF basic. After incubation for 24-48 hours, the supernatant was collected, filtered and stored at À801C until following use. The method of infecting the NSCs was the same as previously described. 9 Briefly, the NSCs were plated as 6 Â 10 4 /well with 2 ml of NSC growth medium into an ultra-low-attachment six-well cluster and incubated for 2 hours. Thereafter, 1 ml of the supernatant of HSVtk retrovirus was added. The NSCs were incubated in the presence of 8 mg/ml Polybrene (Aldrich Chemical Company Inc., Milwaukee, WI) for 3 hours. After washing, the cells were maintained with fresh NSC growth medium for 2 days. The neurospheres were then collected by centrifugation (40 g for 5 minutes), and dissociated into single cells. The drug selection with 150 mg/ml G418 (Sigma-Aldrich Japan KK, Tokyo) was performed for 1 week. The drug-resistant neurospheres were collected one by one and passed separately into an ultra-low-attachment 96-well cluster. The NSCs were incubated until sufficient numbers of cells were obtained.
In vitro sensitivity of TK neural stem (NSCtk) to GCV To test the sensitivity to GCV, the obtained NSCtk clones were cultured in the NSC growth medium containing various concentrations (.01-300 mg/ml) of GCV (Syntex Chemical Inc., Palo Alto, CA) in an ultra-low-attachment 96-well cluster (1 Â 10 4 cells/well). The clone, having a high GCV sensitivity and the same in vitro proliferative activity as wild-type NSCs, was used for further experiments (NSCtk cells). NSCtk or wild-type NSCs were cultured in the NSC growth medium containing various concentrations of GCV described above in an ultra-lowattachment 96-well cluster and were incubated for 7 days. Viability of the cells was estimated using Tetrozoliumbased colorimetric assay (MTT assay). 10 In vitro bystander tumoricidal effect in rat C6 glioma cell line
The C6 rat glioma cell line was purchased from ATCC (Manassas, VA). The cells (5 Â 10 3 ) were co-cultured with/without the same number of NSCtk or wild-type NSCs in complete DMEM medium containing .01-10 mg/ ml GCV in a 96-well tissue culture plate. As another control, 5 Â 10 3 C6 cells were cultured alone in the medium containing GCV or not. The GCV conditional medium was changed every 2 days and the number of living cells was determined by MTT assay on day 10. Sensitivity to GCV was expressed as percent absorbance of the control C6 cells cultured without GCV.
In vivo bystander effect between NSCtk and C6 cells in nude mice
In all, 24 female BALB/c nude mice (19-21 g, 9 weeks old, Nippon SLC, Hamamatsu) were anesthetized with .4 ml/ 100 g equithesin and placed in a stereotaxic apparatus (Narishige Scientific Instrument Lab., Tokyo). The bregma and lambda were placed in the same horizontal plane. The scalp was incised at the midline and retracted laterally to make a burr hole at an appropriate location (co-ordinates with respect to bregma: .2 mm posterior, 2 mm right). A 25-gauge needle was inserted to the point of 4 mm ventral from the dura, left in position for a minute, and then withdrawn to the point of 3 mm ventral from the dura, where 2 Â 10 4 C6 cells with/without 2 Â 10 (Hamilton Company, Reno, NV) and a microinjector (Harvard Apparatus Inc., South Natick, MA) for 5 minutes. The needle was kept in place for an additional minute before removal. In all, 12 mice were implanted with a mixture of C6 and NSCtk cells in 2 ml DMEM medium, and the other 12 mice, with C6 cells (2 Â 10 4 ) only in 2 ml DMEM medium. Half of the animals (n ¼ 6) for each group underwent intraperitoneal administration of 50 mg/kg of GCV twice daily (100 mg/kg/day) from day 0 for 10 days, and the other half (n ¼ 6), physiological saline (PS). The animals were kept under the same laboratory conditions. No steroids or antibiotics were used. All the animals were killed on day 21 and histological analyses were performed. Serial coronal sections (5 mm) were obtained and stained with hematoxylin and eosin. The tumor area of each section was measured using NIH Image software (rsbweb.nih.gov). The total volume of the tumor (mm 3 ) was calculated by summing up the cross-sectional areas.
Another 24 mice were treated in the same way as above (six for each group) for the survival study. When the mice developed symptoms such as severe paresis and/or ataxia, or when their body weight decreased to less than 80%, they were killed. Survival was analyzed by a log-rank test based on the Kaplan-Meier test using Statview 5.0 software.
In vivo bystander effect between NSCtk and C6 cells in Sprague-Dawley rats
A total of 42 male Sprague-Dawley rats (280-320 g, 9 weeks old, Nippon SLC, Hamamatsu) were anesthetized with .4 ml/100 g equithesin and placed in the stereotaxic apparatus. The method followed was the same as described above, except the position and the amount of implanting cells. Briefly, 1 Â 10 5 C6 cells with 1 Â 10 5
NSCtk cells in 10 ml DMEM medium were infused with a 50 ml microsyringe to the point of 5 mm ventral from the dura through the burr hole (co-ordinates with respect to bregma: 2 mm posterior, 3 mm right). Either 15 mg/kg GCV twice daily (30 mg/kg/day, n ¼ 14) or PS (n ¼ 14) was intraperitoneally administered from day 0 for 10 days. As a control, another 14 rats, infused with 1 Â 10 5 C6 cells only in 10 ml DMEM medium, underwent intraperitoneal administration of PS. In all, 18 rats (six rats for each group) were killed on day 14 for histological examination and the other 24 rats (eight rats for each group) served as the survival study group.
Treatment of intracranial C6 tumors in Sprague-Dawley rats through the bystander effect generated with intratumoral injection of NSCtk cells followed by GCV administration A total of 21 male Sprague-Dawley rats underwent implantation of 1 Â 10 5 C6 cells in 10 ml DMEM medium at the same stereotaxic co-ordinates as the previous experiment (co-ordinates with respect to bregma: 2 mm posterior, 3 mm right, 5 mm ventral from the dura). At 7 days after the tumor implantation, all animals were anesthetized and placed on a surface coil for human study in a .3 T MRI device (AIRIS-II comfort, Hitachi Medical Co., Tokyo). After injection of gadolinium-diethylenetriaminepenta-acetic acid (Gd-DTPA, .8-1.0 ml/kg), coronal T 1 weighted images (TR 400 msec, TE 25 msec, 3 mm thickness, gapless) were obtained. After confirming the tumor existence, 15 rats were injected with 2 Â 10 6 NSCtk cells at the same stereotaxic co-ordinates as the C6 cells were implanted 7 days before, and six rats with medium alone (intraperitoneal administration of PS for 10 days). Nine of the 15 rats injected with NSCtk cells underwent intraperitoneal administration of 15 mg/kg GCV twice daily (30 mg/kg/day) from the day of NSCtk injection for 10 days, and the six other rats were administered with PS. Serial MRI studies were performed every 7 days and tumor volume (mm 3 ) was measured as the sum of the Gd-enhanced portion judged by each MR imaged area (mm 2 ) times the image thickness (3 mm). Survival time of the rats was also recorded.
Results
In vitro sensitivity of NSCtk cells to GCV
To test the sensitivity to GCV, all the NSCtk clones obtained were cultured in the presence of various concentrations of GCV (.01-300 mg/ml). Since NSCtk clones exhibited quite different sensitivity to GCV, we selected one clone which had the highest sensitivity to GCV and had the same in vitro proliferative activity as wild-type NSCs (data not shown). MTT assay showed that the viability of NSCtk cells was drastically decreased at .1 mg/ml of GCV and almost no NSCtk cells survived at 3 mg/ml (Fig 1) . In contrast, no significant toxicity was observed in wild-type NSCs. The 100% lethal dose of GCV for wild-type NSCs was 300 mg/ml, which was 100 times higher than that for NSCtk cells. Figure 1 In vitro sensitivity of NSCtk cells and wild-type NSCs to GCV (.01-300 mg/ml) evaluated by the MTT assay (triplicate, mean7standard error). Sensitivity of NSCtk to GCV ('), expressed as percent absorbance of control cells cultured without GCV, was much higher than that of wild-type NSCs (&). Survival of NSCtk cells was significantly lower than that of wild-type NSCs at the GCV concentrations as low as .1 mg/ml (*Po.01).
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In vitro bystander tumoricidal effect in the rat C6 glioma cell line
The proliferation activity of C6 cells assessed by MTT assay was inhibited only when they were co-cultured with NSCtk cells and not with wild-type NSCs in GCVcontaining medium. The GCV-containing medium alone did not show any effect on the viability of C6 cells (Fig 2) . Approximately 70% inhibition was observed at .3 ml/ml of GCV, and almost no viable cells were observed at 1 mg/ml of GCV. No proliferation inhibition of C6 cells was observed when they were co-cultured with wild-type NSCs, and there was no significant difference in proliferation between C6 cells alone and C6 cells cocultured with wild-type NSCs at any GCV concentration (Fig 2) .
In vivo bystander effect in the co-implantation experiments in nude mice and Sprague-Dawley rats A total of 48 female BALB/c nude mice underwent intracranial implantation of 2 Â 10 4 C6 cells with/without 2 Â 10 4 NSCtk cells, and intraperitoneal administration with GCV or PS was carried out for 10 days for measurement of the tumor volume (n ¼ 24) and survival study (n ¼ 24). On histological examination on day 21, all the mice, except the mice of the C6/NSCtk co-implantation group treated with GCV, developed a large tumor (Fig 3a-c) . On the other hand, no visible brain tumors were found in all six mice of the C6/NSCtk(GCV) group (Fig 3d) . The measured tumor volume was shown in Figure 3e . All the mice in the C6(PS), C6(GCV) and C6/ NSCtk(PS) groups died 3-4 weeks after the tumor implantation, while all six mice of the C6/NSCtk(GCV) group survived longer than 100 days (Fig 3f) .
In total, 42 male Sprague-Dawley rats underwent intracranial implantation of 1 Â 10 5 C6 cells with/without 1 Â 10 5 NSCtk cells and intraperitoneal administration with GCV or PS was performed for 10 days for measurement of the tumor volume (n ¼ 18) and survival (n ¼ 24) as in the previous nude mice experiments. All the rats underwent C6(PS) or co-implantation of C6/ NSCtk(PS) developed a large tumor (Fig 4a and b) , whereas no visible brain tumors were found in the rats of the C6/NSCtk(GCV) group (Fig 4c) . The measured tumor volume was shown in Figure 4d . The rats in the C6(PS) and C6/NSCtk(PS) groups died 2-3 weeks after tumor implantation, while the eight rats in the C6/NSCtk(GCV) group survived more than 100 days (Fig 4e) .
Treatment of intracranial C6 tumors in Sprague-Dawley rats through the bystander effect generated with intratumoral injection of NSCtk cells followed by GCV administration
Since the previous co-implanted experiments in SpragueDawley rats showed no visible brain tumors when treated with GCV, in the next protocol, we attempted to treat a pre-existing brain tumor through the bystander effect generated by intratumoral injection of NSCtk cells followed by GCV administration. In all, 21 male Sprague-Dawley rats underwent intracranial implantation of 1 Â 10 5 C6 cells. After confirming the tumor existence with MRI on day 7, 15 rats were injected with 2 Â 10 6 NSCtk cells at the same stereotaxic co-ordinates (C6/NSCtk( þ )).The C6/NSCtk( þ ) rats were intraperitoneally treated with either GCV (n ¼ 9) or PS (n ¼ 6) for 10 days. The other six rats were injected with medium alone (C6/NSCtk(À)) and treated with PS. Gd-DTPAenhanced MRI was taken every 7 days until 70 days for measurement of tumor volume. Representative MRIs are shown in Figure 5 . The tumors in the control groups (C6/NSCtk(À)(PS) and C6/NSCtk( þ )(PS)) for each group progressively enlarged (Figs 5a and 6a , open squares and open triangles, respectively) and all the rats died by 22 days after tumor implantation (Fig 6b) . The survival of the C6/NSCtk(À)(PS) group was not different from that of the C6/NSCtk( þ )(PS) group. In contrast, six of nine rats of the C6/NSCtk( þ )(GCV) group showed a decrease in tumor size from the second week and survived longer than 70 days without visible brain tumors (Figs 5c and 6a, closed triangles) and the final survival was over 100 days (Fig 6b) . The other three of the nine rats died at 21, 36 and 70 days (Fig 6a and b) .
Discussion
Since gliomas scarcely spread outside the central nervous system, local tumor control would be directly linked to a prolonged survival. HSVtk/GCV gene therapy has been considered as one of the most promising therapeutic strategies for malignant gliomas. When tumor cells are transduced with the HSVtk gene and exposed to GCV, phosphorylated GCV, which is formed by HSVtk but not by mammalian enzymes, blocks DNA replication, Suicide gene therapy using neural stem cells S Li et al resulting in consequent cell death. 11, 12 Use of a retroviral system for gene transduction is especially suitable for gliomas because the retrovirus integrates preferentially into the genome of actively dividing tumor cells, but not into postmitotic brain cells. Furthermore, the bystander effect, in which HSVtk-nontransduced cells as well as HSVtk-transduced cells are killed, 3 covers the low transduction rate of retroviral systems. For these reasons, several clinical studies using retrovirus-mediated HSVtk/ GCV systems have been carried out for the treatment of malignant gliomas, but with no therapeutic benefits. 13 The clinical safety of the treatment was proved, but no significant survival improvement was obtained. The failure of this specific protocol may be partly due to the use of fibroblasts as vector-producing cells. Nonmigratory fibroblasts cannot cover all of the glioma cells in those tumors that expand, infiltrate surrounding tissue, and migrate widely into distant normal brain. However, the bystander effect in the HSVtk/GCV gene therapy system is still a very attractive phenomenon for the treatment of gliomas. In order to increase the migratory potential of the vector cells and expand the gene delivery areas in the HSVtk/GCV gene therapy, we first used TK tumor cells in the previous studies, 4, 5 and then NSCtk in the present study.
We have shown that TK tumor cells exhibited a potent bystander effect and that the effect depended on the condition of the intercellular gap junctions. 14 The results of the present study demonstrated that the in vitro bystander effect between NSCtk and C6 cells (Fig 2) was much more potent than that between the HSVtktransduced and HSVtk-nontransduced 9L rat glioma cells that had high expression of connexin43, a major protein in the connexin family gene products. 14 The reasons for this extremely potent bystander effect between NSCtk and tumor cells in the present study are not fully understood and further studies are needed to elucidate the mechanism. Hamel et al. 15 detected apoptosis in bystander cells and found that bystander cell death could be inhibited by BCL2 expression. The potent bystander effect observed in the present study may be mediated by apoptosis. Whatever the mechanism would be, this potent bystander effect is extremely beneficial for the clinical use of this strategy.
Neural stem/progenitor cells are multipotential cells that have the capacity to proliferate in an undifferentiated state, to self-renew, and to give rise to all the cell types of the central nervous system. They could proliferate as free floating ''neurospheres'' in vitro and retain the multipotent ability in the presence of mitogen. 16 Since the Suicide gene therapy using neural stem cells S Li et al discovery and characterization of neural stem/progenitor cells, many studies have been performed on neuronal restoration by transplantation after ischemic and traumatic injuries of the central nervous system. 8 It has been shown that neural stem/progenitor cells migrate to the regions where neurogenesis is required such as ischemic and traumatic lesions. Aboody et al. 6 have also demonstrated the exceptional migratory ability of NSCs to brain tumors. NSCs, implanted into experimental intracranial gliomas in adult rats, distributed themselves quickly and extensively throughout the tumor bed and migrated uniquely in juxtaposition to widely expanding and aggressively advancing tumor cells. This migratory potential of therapeutic cells is extremely important for the successful treatment of infiltrative growing tumors such as gliomas.
Neural stem/progenitor cell research has been mainly focused on neuronal restoration after brain injuries, and studies of NSC use for treatment of intracranial malignant brain tumors have been limited. Benedetti et al. 17 first used neural progenitor cells transduced with the interleukin-4 gene for the treatment of C6 gliomas in Sprague-Dawley rats. Another group used NSCs secreting interleukin-12 18 and tumor necrosis factor-related apoptosis-inducing ligand 19 for the treatment of gliomas in rodents. As for suicide gene therapies, a combination of cytosine deaminase-expressing immortalized neural progenitor cells and 5-fluorocytosine was used for treatment of C6 gliomas in Sprague-Dawley rats. 20 Unlike fibroblasts, from which retrovirus-producing cells (retroviral packaging cells) are derived, NSCs obtained from the same species can engraft stably and are less or not susceptible to immune rejection. 21 We believe that NSCs may provide a unique ''platform'' for delivering the HSVtk gene near to the inaccessible infiltrating tumor cells. We observed, in this first study of NSC use in the Suicide gene therapy using neural stem cells S Li et al HSVtk/GCV suicide gene therapy, such a strong bystander effect that no tumor could be formed in the therapeutic group of the co-implanted experiments.
If a sufficient amount of human NSCtk cells could be available at the time of surgery, those cells could be applied to the cavity walls after tumor removal. Even after gross total tumor removal, some residual tumor cells must be left behind. This could be achieved by in vitro expansion using the Neural stem cell expansion kit/ Neurosphere system now. Those residual cells can be eradicated by applying NSCtk cells on the cavity walls followed by systemic GCV administration. In the case of deep-seated tumors such as thalamic gliomas, injection of NSCtk cells through the biopsy needle that have been used for tumor biopsy may be another application of this strategy. Whenever NSCs are used in a clinical setting, the issue of tumorigenesis of implanted NSCs must be considered. In the present setting, however, all NSCtk cells having proliferative activity were completely eradicated by GCV administration (Fig 1) . Although some cells which have differentiated to neurons and glias may survive, these cells have no ability to proliferate. Therefore, we believe that the risk of tumorigenesis in use of NSCs transduced with HSVtk gene is very low.
Host immunological reactions may occur against reserved NSCtk cells. To circumvent such immune reactions, use of bone marrow-derived cells that can be obtained easily and abundantly from the patients themselves is being studied now. Recently, neural stemlike cells, derived from human adult bone marrow, have been observed that can differentiate into neurons and glias and migrate toward distant sites of brain injury and tumor in vivo in mice. 22 Also, the use of interleukin-2 engineered mesenchymal stem cells as a targeting vehicle was studied in a rat glioma model. 23 In this setting of ours, at the time when the tumor of the patient is diagnosed as malignant glioma by either pre-operative diagnostic imaging or first surgical exploration, bone marrow cells could be obtained from the patient. The bone marrow-derived cells would then be transduced with the HSVtk gene and propagated to a sufficient amount. Those cells would be injected into the tumor cavity walls after maximum tumor removal, and then GCV would be administered. Autologous neural stem-like cells obtained from the bone marrow may be used as a tool for future therapeutic strategies.
In the present study, we administered GCV immediately after the intratumoral injection of NSCtk cells. Three of the nine rats in the treatment of pre-existing intracranial C6 tumors died of tumor progression after they were treated with intratumoral injection of NSCtk cells followed by GCV administration (Fig 6a and b) . This is probably because the migration of NSCtk cells could not cover the whole tumor. Better results may be expected if GCV is given after a certain period during which NSCtk cells can proliferate and migrate further from the injected site. The same number of NSCtk cells was used in the present study, but the co-culture study and preliminary co-implanted study suggest that a smaller number of NSCtk cells are also effective (data not shown). Further detailed experiments are needed to determine the optimum number of NSCtk injections and the optimum timing of GCV administration before preparing a clinical protocol for the treatment of malignant glioma. The HSVtk/GCV gene therapy has been one of the most promising glioma therapies, so far, because of its potent bystander effect. The present study strongly suggests that the use of NSCs in HSVtk/GCV gene therapy is feasible and could provide a breakthrough in the treatment of malignant gliomas that is inevitably fatal at the present time. Suicide gene therapy using neural stem cells S Li et al
